CommercialCoverageMedium impact
08.02.33a, Guselkumab (Tremfya®) Injection for Intravenous Use
Independence Blue Cross·Dermatology, Rheumatology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
The medical necessity criteria and general guidelines for Guselkumab (Tremfya®) intravenous injection have been updated for commercial plans. This affects coverage requirements and documentation standards for this specialty biologic medication used primarily in dermatology and rheumatology.
Action Required
By July 1, 2025: Billing team must review updated medical necessity criteria for Guselkumab (Tremfya®) IV injections for commercial patients. Update prior authorization documentation requirements and inform providers of any new coverage guidelines. Verify current criteria in billing system to ensure claims compliance.